ArticleScience advances2019
Inhibiting the stringent response blocks
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed
10.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 130 citations in OpenAlex.
- Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV.Frontiers in immunology · 2021Trial
- Reactive oxygen detoxification contributes toeLife · 2026Article
- Structural and functional characterization of VapBC52 toxin-antitoxin system from Mycobacterium tuberculosis.Nucleic acids research · 2026Article
- Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models.The Journal of clinical investigation · 2026Article
- Reactive Oxygen Detoxification Contributes tobioRxiv : the preprint server for biology · 2025Article
- Genetic determinants ofMicrobiology spectrum · 2025Article
- MIP3α-RelVaccine · 2025Article
- Analysis of (p)ppGpp metabolism and signaling using a dynamic luminescent reporter.PLoS genetics · 2025Article
- MIP-3α-antigen fusion DNA vaccine enhances sex differences in tuberculosis model and alters dendritic cell activity early post vaccination.Scientific reports · 2025Article
- Effect of host microenvironment and bacterial lifestyles on antimicrobial sensitivity and implications for susceptibility testing.npj antimicrobials and resistance · 2025Review
- Broad-spectrum tolerance to disinfectant-mediated bacterial killing due to mutation of the PheS aminoacyl tRNA synthetase.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Targeting the bacterial stringent response to combat human pathogens.Frontiers in immunology · 2025Review
- Molecular characteristics of drug-susceptible Mycobacterium tuberculosis clinical isolates based on treatment duration.Osong public health and research perspectives · 2024Article
- Mycobacterial Biofilm: Mechanisms, Clinical Problems, and Treatments.International journal of molecular sciences · 2024Review
- Gene Regulatory Mechanism of Mycobacterium Tuberculosis during Dormancy.Current issues in molecular biology · 2024Review
- Navigating Antibacterial Frontiers: A Panoramic Exploration of Antibacterial Landscapes, Resistance Mechanisms, and Emerging Therapeutic Strategies.ACS infectious diseases · 2024Review
- Syringaldehyde Exhibits Antibacterial and Antioxidant Activities againstMicroorganisms · 2024Article
- Metabolic Rewiring ofMetabolites · 2024Review
- Polyphosphate kinase-1 regulates bacterial and host metabolic pathways involved in pathogenesis ofProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Antibiotic heteroresistance and persistence: an additional aid in hospital acquired infections byFuture microbiology · 2024Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 2 countries.
Noton K DuttaDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-5066-3342
Lee G KlinkenbergDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-7500-4546
Maria-Jesus VazquezMedical Department, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Delfina Segura-CarroDiseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain.ORCID 0000-0002-0160-7993
Gonzalo ColmenarejoMolecular Discovery Research, GlaxoSmithKline, Tres Cantos, Madrid, Spain.ORCID 0000-0002-8249-4547
Fernando RamonMolecular Discovery Research, GlaxoSmithKline, Tres Cantos, Madrid, Spain.ORCID 0000-0002-0770-2553
Beatriz Rodriguez-MiquelDiseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain.ORCID 0000-0002-7638-8705
Lydia Mata-CanteroDiseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Esther Porras-De FranciscoDiseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain.ORCID 0000-0002-1298-2318
Yu-Min ChuangDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Harvey RubinDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jae Jin LeeDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of USC, Los Angeles, CA, USA.ORCID 0000-0001-8317-437X
Hyungjin EohDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of USC, Los Angeles, CA, USA.
Joel S BaderDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-6020-4625
Esther Perez-HerranDiseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Alfonso Mendoza-LosanaDiseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain.ORCID 0000-0003-2493-4118
Petros C KarakousisDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-1338-9206
GlaxoSmithKline (Spain) · ESJohns Hopkins University · USKeck Hospital of USC · USMadrid Institute for Advanced Studies · ESUniversity of Pennsylvania · US
Funding
Regulatory networks involved in Mycobacterium tuberculosis persistenceR01AI083125 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KARAKOUSIS, PETROS C · 2009 to 2013
$2.7MValidation of RelA as a Target for Mycobacterium Tuberculosis PersistersR21AI114507 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KARAKOUSIS, PETROS C · 2015 to 2016
$446kA novel "shock and kill" strategy for eliminating Mtb persisters in the CD4 T-cell-deficient hostR21AI122922 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KARAKOUSIS, PETROS C · 2016 to 2017
$446kNIAID NIH HHS R01 AI083125NIAID NIH HHS R21 AI114507NIAID NIH HHS R21 AI122922
Abstract
The stringent response enables
Indexed as
AnimalsBacterial ProteinsCrystallography, X-RayDNA ReplicationEscherichia coli ProteinsGTP PyrophosphokinaseHumansIntracellular Signaling Peptides and ProteinsIsoniazidMiceMycobacterium tuberculosisProtein ConformationSmall Molecule LibrariesTranscription Factor RelATuberculosisBacterial ProteinsEscherichia coli ProteinsGTP PyrophosphokinaseIntracellular Signaling Peptides and ProteinsIsoniazidrelA protein, E coliRshA protein, Mycobacterium tuberculosisSmall Molecule LibrariesTranscription Factor RelA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.